Editas Medicine (EDIT) Stifel 2024 Healthcare Conference summary

Strategic focus and program updates

• Three-pillar strategy centers on reni-cel (autologous sickle cell therapy), in vivo gene editing, and leveraging foundational IP for non-dilutive capital.

• Reni-cel is being positioned for partnership due to capital constraints and to maximize patient reach, while in vivo programs are prioritized for long-term growth.

• In vivo proof-of-concept was achieved in extrahepatic tissue using proprietary LNP technology, targeting sickle cell and beta thalassemia.

• The company is focused on high-conviction, first-in-class targets, avoiding crowded indications and aiming for rare diseases with significant unmet need.

• Genevant partnership supports liver-targeted programs, while internal LNPs focus on HSCs; both approaches align with the strategy to avoid direct competition and maximize commercial viability.

Reni-cel clinical and differentiation highlights

• Upcoming ASH data update will include 28 patients with extended follow-up, showing sustained VOE-free status and correction of anemia.

• Mean total hemoglobin remains above 14, indicating normalization and potential improvement in patient quality of life.

• RUBY study shows mean mobilization cycles of two (range 1–4), while EdiTHAL achieved mobilization in one cycle; rapid neutrophil engraftment may reduce hospital stays.

• Market launch for similar therapies has been slow due to contracting and reimbursement cycles, but patient awareness and enrollment are increasing.

• Enrollment for reni-cel is complete; ongoing activities focus on capital allocation and preparing for potential BLA submission while seeking a partner.

Financials, partnerships, and forward outlook

• Vertex deal brought in $50 million upfront, with annual license payments of $10–$40 million through 2033 and additional contingent payments; $80 million in non-dilutive capital was raised in one year.

• Cash runway extends into Q2 2026, with a pro forma cash position of approximately $320 million after the DRI deal.

• Commercial focus is on rare diseases with peak sales potential of at least $500 million, avoiding crowded markets and leveraging pricing models to ensure returns.

• The company plans to provide incremental data updates for in vivo programs, emphasizing transparency and investor engagement.

• Manufacturing strategies for LNPs are modeled on capital-efficient approaches, with external capacity available as needed.